Trends and determinants of severe morbidity in HIV-infected patients: The ANRS CO3 Aquitaine Cohort, 2000-2004

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 547-554

  Bonnet, F ^a,b   Chene G ^b   Thiebaut R ^b   Dupon, M ^a   Lawson ayayi, S ^a,b   Pellegrin, J L ^a   Dabis, F ^a,b   Morlat, P ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Bacterial infections; Cancers; Epidemiology; HIV; Morbidity; Opportunistic infections

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTERIAL INFECTION; CANCER; CARDIOVASCULAR DISEASE; DEVELOPED COUNTRY; DIGESTIVE SYSTEM DISEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; MORTALITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; TREND STUDY; VIRUS INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 35448937261     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00508.x     Document Type: Article

References (22)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Bonnet F, Morlat P, Chêne G et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2002; 3: 195-199.
3. Lewden C, Salmon D, Morlat P et al. Causes of death among HIV-infected adults living in industrialized countries. A national study over the year 2000. Int J Epidemiol 2005; 34: 121-130.
4. Beck EJ, Mandalia S, Williams I et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. AIDS 1999; 13: 2157-2164.
5. Mocroft A, d'Arminio Monforte A, Kirk O et al. Changes in hospital admissions across Europe: 1995-2003. Results from the Euro SIDA study. HIV Med 2004; 5: 437-447.
6. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 143-152.
7. Floris-Moore M, Lo Y, Klein RS et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 331-337.
8. World Health Organization. International Classification of Diseases. 10th Revision. Geneva: WHO, 1993.
9. Thiébaut R, Morlat P, Jacqmin-Gadda H et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14: 971-978.
10. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
11. Bénard A, Tessier JF, Rambeloarisoa J et al. HIV infection and smoking behaviour: Prospects for prevention? ANRS Aquitaine Cohort, 2002. Int J Tuberc Dis 2006; 10: 378-383.
12. Bénard A, Bonnet F, Tessier JF et al. Tobacco addiction and HIV infection: Toward the implementation of cessation programs. A cross-sectional survey in the ANRS CO3 Aquitaine Cohort, 2004. AIDS Patients Care and STDs 2007; 21: 458-468.
13. Bing EG, Burnam MA, Longshore D et al. Psychiatric disorders and drug use among HIV-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721-728.
14. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
15. d'Arminio A, Sabin CA, Phillips AN et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18: 1811-1817.
16. Thiébaut R, Aurillac-Lavignolle V, Bonnet F et al. Change in atherosclerosis progression in HIV infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS 2005; 19: 729-731.
17. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
18. Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 3447-3453.
19. Clifford GM, Polesel J, Rickenbach et al. Cancer risk in the Swiss HIV Cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Nat Cancer Inst 2005; 97: 425-432.
20. US Centers for Disease Control and Prevention. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity Mortality Wkly Rep 1992; 41: 1-19.
21. Zwahlen M, Lundgren JD Commentary: Death in the era of potent antiretroviral therapy: Shifting causes, new challenges. Int J Epidemiol 2005; 34: 130-131.
22. Mocroft A, Gatell J, Reiss P et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004; 18: 2333-2337.